MG
MLTX icon

Michael Gelband’s MoonLake Immunotherapeutics MLTX Stock Holding History

Michael Gelband’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,000
Closed -$215K – 1859
2025
Q3 		$215K Buy
+30,000
New +$1.56M ﹤0.01% 1373

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Michael Gelband's MLTX Position: Q2 2026 in Review

Michael Gelband reduced its MoonLake Immunotherapeutics (MLTX) stake by 61% in Q2 2026, selling an estimated $1.34M and leaving 46,646 shares worth $908K. The position accounts for 0.01% of the portfolio, ranked #1101.

Michael Gelband first reported a position in MLTX in Q4 2020 and has held it in 12 quarters since. The position peaked at $2.81M in Q4 2025. 171 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Michael Gelband held 46,646 shares of MoonLake Immunotherapeutics worth $908K as of Q2 2026.
  • Michael Gelband sold 73,664 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.34M.
  • MoonLake Immunotherapeutics made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #1101 holding.
  • Michael Gelband first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 12 quarters since.
  • Michael Gelband's MoonLake Immunotherapeutics position peaked at $2.81M in Q4 2025.
  • 171 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.